These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31309879)

  • 41. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
    Balakin KV; Ivanenkov YA; Kiselyov AS; Tkachenko SE
    Anticancer Agents Med Chem; 2007 Sep; 7(5):576-92. PubMed ID: 17896917
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of histone deacetylation: a strategy for tumor radiosensitization.
    Camphausen K; Tofilon PJ
    J Clin Oncol; 2007 Sep; 25(26):4051-6. PubMed ID: 17827453
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of Histone Deacetylases in the Pathogenesis of Salivary Gland Tumors and Therapeutic Targeting Options.
    Manou M; Kanakoglou DS; Loupis T; Vrachnos DM; Theocharis S; Papavassiliou AG; Piperi C
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HDAC modulation and cell death in the clinic.
    Dell'Aversana C; Lepore I; Altucci L
    Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
    Petta V; Gkiozos I; Strimpakos A; Syrigos K
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting histone deacetylases in neuroblastoma.
    Witt O; Deubzer HE; Lodrini M; Milde T; Oehme I
    Curr Pharm Des; 2009; 15(4):436-47. PubMed ID: 19199971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The emerging role of histone deacetylases (HDACs) in UPR regulation.
    Kahali S; Sarcar B; Chinnaiyan P
    Methods Enzymol; 2011; 490():159-74. PubMed ID: 21266250
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer.
    Marson CM
    Anticancer Agents Med Chem; 2009 Jul; 9(6):661-92. PubMed ID: 19601748
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis.
    Chen PJ; Huang C; Meng XM; Li J
    Biochimie; 2015 Sep; 116():61-9. PubMed ID: 26116886
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemical and structural biology of protein lysine deacetylases.
    Yoshida M; Kudo N; Kosono S; Ito A
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(5):297-321. PubMed ID: 28496053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
    Collier CD; Getty PJ; Greenfield EM
    Adv Exp Med Biol; 2020; 1258():55-75. PubMed ID: 32767234
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM
    Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKCα-mediated AHR-HDAC interactions.
    Tsai CH; Li CH; Liao PL; Chang YW; Cheng YW; Kang JJ
    Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118564. PubMed ID: 31672612
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting histone deacetylase in thyroid cancer.
    Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
    Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiproliferative and proapoptotic activities of 4-hydroxybenzoic acid-based inhibitors of histone deacetylases.
    Seidel C; Schnekenburger M; Dicato M; Diederich M
    Cancer Lett; 2014 Feb; 343(1):134-46. PubMed ID: 24080339
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Sensitive and Flexible Assay for Determining Histone Deacetylase 1 (HDAC1) Activity.
    Wu MY; Wu RC
    Methods Mol Biol; 2016; 1436():3-13. PubMed ID: 27246204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.